Embattled fertility giant Monash IVF Group (ASX:MVF) has reached an out-of-court settlement with families affected by two high-profile embryo mix-ups at its clinics in Brisbane and Melbourne.
The ASX-listed provider confirmed that it had resolved "material claims" stemming from the 2023 incidents, which saw one patient unknowingly give birth to another couple’s biological child.
In the Brisbane case, an incorrect embryo transfer led to a "wrongful birth," while a separate Melbourne incident involved the misidentification of a partner’s embryo.
While the settlement figures and identities of the families remain confidential, a company spokeswoman expressed deep regret, stating that Monash has since "taken significant steps to strengthen safety culture and enhance oversight."
The reputational fallout has been severe. Monash shares, which plummeted 50% when the errors were first disclosed, traded at 66 cents on March 2—a far cry from the 80 cents valuation seen during a rejected $312 million takeover bid by Genesis Capital in November.
The settlement follows a separate $56 million class-action payout last year concerning destroyed healthy embryos due to faulty genetic screening.
As the company battles to recover dwindling market share and patient trust, the departure of CEO Michael Knaap in June underscores the leadership crisis triggered by these procedural failures.
At the time of reporting, Monash IVF's share price was $0.65.